TScan Therapeutics will present at the TD Cowen Health Care Conference on March 4, 2026, livestreaming available.
Quiver AI Summary
TScan Therapeutics, Inc., a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer treatment, announced its participation in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, at 11:50 a.m. Eastern Time. The event will feature a hybrid presentation followed by a Q&A session led by analysts, and a webcast will be available on the Company's website, with a replay accessible for 90 days after the event. TScan's lead therapy candidate is currently being evaluated in the ALLOHA™ Phase 1 trial for hematologic malignancies, and the company is also working on therapies for solid tumors and exploring targets for autoimmune disorders.
Potential Positives
- TScan Therapeutics will present at the TD Cowen 46th Annual Health Care Conference, increasing visibility among investors and industry peers.
- The company is showcasing its lead TCR-T therapy candidate aimed at treating hematologic malignancies, reinforcing its innovative approach in the cancer treatment arena.
- The event includes an analyst-led Q&A session, allowing for interactive engagement with industry experts and potential investors.
- A webcast of the presentation will ensure broad accessibility and can extend the reach of the company's messaging, with an archived replay available for 90 days.
Potential Negatives
- Participation in the health care conference may indicate a need for increased investor confidence, suggesting potential challenges in gaining traction or visibility for their TCR-T therapies.
- The focus on clinical-stage status might highlight a lack of approved products, which could be a concern for investors regarding the company's short-term financial viability.
- The emphasis on multiple therapy candidates, while promising, may also raise questions about resource allocation and the likelihood of successful outcomes across various projects.
FAQ
When is TScan Therapeutics' presentation at the TD Cowen Health Care Conference?
TScan Therapeutics will present on March 4, 2026, at 11:50 a.m. Eastern Time.
How can I access the webcast of TScan's presentation?
The webcast can be accessed in the “Events and Presentations” section of TScan's website at ir.tscan.com.
Will there be a recording available after the presentation?
Yes, an archived replay of the webcast will be available for 90 days following the event.
What therapies is TScan focusing on in their clinical development?
TScan is focused on TCR-engineered T cell therapies for cancer treatment, particularly for hematologic malignancies.
Who should I contact for more information about TScan?
For inquiries, contact Troy Neubecker at 857-399-9517 or [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TCRX Insider Trading Activity
$TCRX insiders have traded $TCRX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TCRX stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT LP LYNX1 has made 3 purchases buying 161,801 shares for an estimated $145,525 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TCRX Hedge Fund Activity
We have seen 26 institutional investors add shares of $TCRX stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROPEL BIO MANAGEMENT, LLC removed 1,932,304 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,932,304
- ALPHABET INC. removed 1,077,080 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,077,080
- SIMPLIFY ASSET MANAGEMENT INC. removed 904,972 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $904,972
- MORGAN STANLEY removed 621,708 shares (-73.4%) from their portfolio in Q4 2025, for an estimated $621,708
- TANG CAPITAL MANAGEMENT LLC removed 553,869 shares (-92.3%) from their portfolio in Q4 2025, for an estimated $553,869
- BLACKROCK, INC. removed 534,069 shares (-22.4%) from their portfolio in Q4 2025, for an estimated $534,069
- ABERDEEN GROUP PLC added 430,421 shares (+31.8%) to their portfolio in Q4 2025, for an estimated $430,421
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TCRX Analyst Ratings
Wall Street analysts have issued reports on $TCRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
- Needham issued a "Buy" rating on 11/04/2025
To track analyst ratings and price targets for $TCRX, check out Quiver Quantitative's $TCRX forecast page.
$TCRX Price Targets
Multiple analysts have issued price targets for $TCRX recently. We have seen 2 analysts offer price targets for $TCRX in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $7.0 on 11/13/2025
- Gil Blum from Needham set a target price of $6.0 on 11/04/2025
Full Release
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46 th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 2026 at 11:50 a.m. Eastern Time.
A webcast of the presentation will be available on the “ Events and Presentations ” section of the Company’s website at ir.tscan.com . An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA ™ Phase 1 heme trial). The Company has developed multiple TCR-T therapy candidates for solid tumors and is currently developing methods for in vivo engineering using these candidates. The Company is also applying their target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.
Contacts
Troy Neubecker
TScan Therapeutics, Inc.
Investor Relations
857-399-9517
[email protected]
Caileigh Dougherty
Media Contact
857-399-9890
[email protected]
